Yun Shao1, Xiaoying Li2, Yali Lu2, Lin Liu2, Po Zhao2. 1. Department of Pathology, Chinese People's Liberation Army (PLA) General Hospital 28 Fuxing Road, Beijing 100853, China ; Department of Pathology, Chinese People's Liberation Army (PLA) 307 Hospital China. 2. Department of Pathology, Chinese People's Liberation Army (PLA) General Hospital 28 Fuxing Road, Beijing 100853, China.
Abstract
BACKGROUND: The Leukemia related protein 16 gene (LRP16) localized on chromosome 11q12.1, is an important estrogen-responsive gene and a crucial regulator for NF-kB activation. LRP16 is frequently expressed in human cancers; however, the LRP16 gene remains unexplored in lung neuroendocrine tumors. The aim of this study was to investigate the role of LRP16 expression in primary lung neuroendocrine tumors. METHODS: lung neuroendocrine tumors were analyzed for LRP16 gene expression by two-step non-biotin immunohistochemical method. RESULTS: Fifty of ninety (55.6%) cases of neuroendocrine lung tumors tested were positive for LRP16 protein by immunohistochemistry. The expression of LRP16 was mainly located in cytoplasm and nucleus of tumor cells. LRP16 protein was corresponding to tumor type and clinical stage, as well as survival time. CONCLUSIONS: The results indicate that abnormal LRP16 expression is noted in neuroendocrine lung tumors and the expression can give insight into the pathogenesis of the disease. The LRP16 protein may serve as a potential marker in predicting prognosis of neuroendocrine lung tumors.
BACKGROUND: The Leukemia related protein 16 gene (LRP16) localized on chromosome 11q12.1, is an important estrogen-responsive gene and a crucial regulator for NF-kB activation. LRP16 is frequently expressed in humancancers; however, the LRP16 gene remains unexplored in lung neuroendocrine tumors. The aim of this study was to investigate the role of LRP16 expression in primary lung neuroendocrine tumors. METHODS:lung neuroendocrine tumors were analyzed for LRP16 gene expression by two-step non-biotin immunohistochemical method. RESULTS: Fifty of ninety (55.6%) cases of neuroendocrine lung tumors tested were positive for LRP16 protein by immunohistochemistry. The expression of LRP16 was mainly located in cytoplasm and nucleus of tumor cells. LRP16 protein was corresponding to tumor type and clinical stage, as well as survival time. CONCLUSIONS: The results indicate that abnormal LRP16 expression is noted in neuroendocrine lung tumors and the expression can give insight into the pathogenesis of the disease. The LRP16 protein may serve as a potential marker in predicting prognosis of neuroendocrine lung tumors.
Authors: Beatrice Ariane Windmöller; Johannes F W Greiner; Christine Förster; Ludwig Wilkens; Fritz Mertzlufft; Jan Schulte Am Esch; Barbara Kaltschmidt; Christian Kaltschmidt; Morris Beshay Journal: Medicine (Baltimore) Date: 2019-12 Impact factor: 1.889
Authors: Haixing Wang; Li Sun; Hua Bao; Ao Wang; Panpan Zhang; Xue Wu; Xiaoling Tong; Xiaonan Wang; Jie Luo; Lin Shen; Yang W Shao; Ming Lu Journal: Chin J Cancer Res Date: 2019-12 Impact factor: 5.087